文献速递淋巴瘤造血干细胞移植与细胞治疗

维布妥昔单抗联合苯达莫司汀:复发或难治性霍奇金淋巴瘤的高活性首次挽救方案

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
PubMed 文献 · Blood · 2018-04-27

这项1/2期研究评估维布妥昔单抗联合苯达莫司汀作为复发或难治性霍奇金淋巴瘤的首次挽救方案。55例患者中,53例可评估疗效者的客观缓解率为92.5%,39例(73.6%)达完全缓解;40例接受自体干细胞移植。中位随访20.9个月,接受移植者估计2年无进展生存率为69.8%,所有患者为62.6%。

要点

  • 53例可评估患者客观缓解率92.5%,完全缓解39例(73.6%)。
  • 40例接受自体干细胞移植,接受移植者估计2年无进展生存率69.8%。
  • 31例(56.4%)发生输注相关反应,多在联合治疗第2周期;方案修订要求预用药后严重程度降低。

核心结论

  • 维布妥昔单抗联合苯达莫司汀作为复发或难治性霍奇金淋巴瘤的首次挽救治疗具有高活性,毒性谱可控。

研究设计与样本

  • 1/2期研究,共纳入55例复发或难治性霍奇金淋巴瘤患者,其中28例原发难治、27例复发。
  • 方案为21天周期:第1天维布妥昔单抗1.8 mg/kg,第1、2天苯达莫司汀90 mg/m2,最多6周期;第2周期后可随时行自体干细胞移植。
  • 移植后或未移植者完成联合治疗后,可接受维布妥昔单抗单药治疗,总治疗最多16周期。

主要发现

  • 联合治疗中位2周期(范围1-6)后,53例可评估疗效患者客观缓解率为92.5%,39例(73.6%)达完全缓解。
  • 40例接受自体干细胞移植;31例(其中25例接受移植)接受维布妥昔单抗单药治疗(中位10周期,范围1-14)。
  • 中位随访20.9个月,接受移植者估计2年无进展生存率为69.8%,所有患者为62.6%。
  • 31例(56.4%)发生输注相关反应,多数发生于联合治疗第2周期;要求预用药的方案修订降低了输注相关反应严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5%, with 39 patients (73.6%) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8% and 62.6% for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4%) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT01874054.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018. PMID: 29703778. doi:10.1182/blood-2017-11-815183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。